About me
About me
Australian Society for Microbiology, Australian Society for Antimicrobials, Australian Society for Biochemistry and Molecular Biology, Adelaide Protein Group, American Society for Microbiology, Member of the Institutional Biosafety Committee.
My research focuses on antimicrobial resistance. ‘Superbugs’ are costing the medical and veterinary industry billions of dollars a year and antimicrobial resistance is one of the world’s most pressing health problems. According to the WHO we are fast approaching a post-antibiotic era where small injuries and minor infections will once again be fatal. Work in my laboratory is aimed at finding novel ways of treating infectious disease by characterising bacterial membrane proteins that are involved in drug resistance and/or virulence and on developing drugs that act on these targets. We are currently working on drug efflux pumps, iron transporters and cell division proteins in pathogenic bacteria. Most of our work... Read more
Research
Excludes commercial-in-confidence projects.
Turning antimicrobial resistance in residential aged care inside-out from the patient to facility level, MRFF - Targeted Call for Research - Antimicrobial Resistance, 26/06/2018 - 30/06/2024
LIXA in vitro and in vivo efficacy study, Neolixir Pty Ltd, 22/04/2024 - 30/06/2024
Reversing antibiotic resistance with efflux pump inhibitors, NHMRC - Project Grant, 01/01/2018 - 31/12/2021
Improving safety of vegetable produce through on‐farm sanitation, using Electrolysed Oxidising (EO) Water - VG15068, Hort Innovation, 01/06/2017 - 31/05/2020
Research Infrastructure Fund (RIF) Grant 2016 Round 2 - Biofilm Testing Facility, Adelaide Integrated Bioscience Laboratories, 28/11/2016 - 31/12/2017
We run an antimicrobial screening facility where we screen natural and synthetic compounds for antimicrobial activity, antibiofilm activity and the reversal of resistance.
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2015 |
Open access
213
201
2
|
2014 |
Open access
85
81
3
|
Year | Output |
---|---|
2020 |
1
2
|
2013 |
|
2008 |
6
|
Year | Output |
---|---|
2024 |
Open access
1
|
2024 |
Open access
|
2024 |
Open access
1
|
2024 |
Open access
1
|
2024 |
Open access
|
2024 |
Open access
1
|
2023 |
Open access
7
|
2023 |
4
4
6
|
2023 |
Open access
5
|
2023 |
Open access
1
|
2023 |
2
3
|
2023 |
5
5
|
2023 |
2
|
2022 |
4
4
|
2022 |
Open access
3
3
4
|
2022 |
Open access
9
11
4
|
2022 |
Open access
5
5
1
|
2022 |
Open access
2
2
4
|
2022 |
Open access
1
1
1
|
2022 |
Open access
1
1
|
2021 |
Open access
12
13
1
|
2021 |
Open access
8
9
77
|
2021 |
Open access
8
7
|
2021 |
12
10
1
|
2021 |
6
12
1
|
2021 |
Open access
1
6
|
2021 |
Open access
10
10
1
|
2021 |
16
15
2
|
2021 |
Open access
7
6
1
|
2021 |
Open access
16
13
|
2021 |
Open access
31
28
2
|
2021 |
Open access
6
5
1
|
2021 |
Open access
49
46
7
|
2021 |
21
22
|
2020 |
Open access
65
57
3
|
2020 |
Open access
12
12
2
|
2020 |
Open access
30
26
|
2020 |
7
8
|
2020 |
15
14
6
|
2020 |
Open access
14
14
4
|
2020 |
15
13
1
|
2019 |
3
3
|
2019 |
Open access
15
13
|
2019 |
Open access
21
19
4
|
2019 |
Open access
19
18
2
|
2019 |
Open access
27
25
1
|
2019 |
Open access
63
62
3
|
2018 |
29
26
1
|
2018 |
28
28
1
|
2018 |
Open access
33
30
1
|
2018 |
21
21
|
2018 |
Open access
24
21
1
|
2018 |
Open access
25
25
4
|
2018 |
34
34
|
2017 |
144
132
38
|
2017 |
29
27
|
2017 |
Open access
28
22
2
|
2017 |
23
24
3
|
2017 |
41
37
|
2017 |
Open access
35
34
1
|
2017 |
Open access
90
75
1
|
2017 |
Open access
34
31
|
2017 |
9
10
3
|
2016 |
Open access
11
9
3
|
2016 |
Open access
23
23
3
|
2016 |
90
85
2
|
2015 |
Open access
213
201
2
|
2014 |
Open access
459
444
9
|
2014 |
Open access
85
81
3
|
2014 |
18
18
|
2012 |
Open access
27
27
|
2010 |
Open access
43
40
|
2009 |
Open access
150
148
|
2009 |
Open access
34
|
2008 |
41
39
|
Research
My research focuses on antimicrobial resistance. ‘Superbugs’ are costing the medical and veterinary industry billions of dollars a year and antimicrobial resistance is one of the world’s most pressing health problems. According to the WHO we are fast approaching a post-antibiotic era where small injuries and minor infections will once again be fatal. Work in my laboratory is aimed at finding novel ways of treating infectious disease by characterising bacterial membrane proteins that are involved in drug resistance and/or virulence and on developing drugs that act on these targets. We are currently working on drug efflux pumps, iron transporters and cell division proteins in pathogenic bacteria. Most of our work focusses on the Gram-negative pathogen P. aeruginosa. This pathogen is associated with a range of life-threatening nosocomial infections and is the main cause of mortality in patients with cystic fibrosis. P. aeruginosa infections are hard to treat since this organism displays resistance against multiple classes of antimicrobials. Central to this bacterium’s high intrinsic drug resistance is the expression of drug efflux pumps and its ability to form antibiotic-tolerant biofilms.
External engagement & recognition
Organisation | Country |
---|---|
Advanced Veterinary Therapeutics | AUSTRALIA |
Ardabil University of Medical Sciences | IRAN |
Baylor College of Medicine | UNITED STATES |
Burnet Institute | AUSTRALIA |
CRC Care | AUSTRALIA |
Deakin University | AUSTRALIA |
Department of Agriculture and Fisheries | AUSTRALIA |
Ecas4 Australia | AUSTRALIA |
Ecas4 Australia Pty Ltd | AUSTRALIA |
Ecas4 Pty Ltd | AUSTRALIA |
Ehime University | JAPAN |
Elizabeth Macarthur Agricultural Institute | AUSTRALIA |
Flinders University | AUSTRALIA |
Ghent University | BELGIUM |
Goethe University Frankfurt | GERMANY |
Harvard University | UNITED STATES |
Ithree Institute | AUSTRALIA |
Kanazawa University | JAPAN |
Liaocheng University | CHINA |
Luoda Pharma | AUSTRALIA |
Luoda Pharma Pty Ltd | AUSTRALIA |
Macquarie University | AUSTRALIA |
Microbial Screening Technologies Pty Ltd | AUSTRALIA |
Micromyx | UNITED STATES |
Monash University | AUSTRALIA |
Murdoch University | AUSTRALIA |
Neoculi Pty. Ltd. | AUSTRALIA |
Northern Technical University | IRAQ |
Pontifical Catholic University of Chile | CHILE |
Qingdao University | CHINA |
Qpex Biopharma | UNITED STATES |
Queensland Department of Agriculture and Fisheries | AUSTRALIA |
ReaLi Tide Biological Technology | CHINA |
ReaLi Tide Biological Technology (Weihai) Co. Ltd | CHINA |
Ritsumeikan University | JAPAN |
Sao Paulo State University | BRAZIL |
Shandong Center for Disease Control and Prevention | CHINA |
Shandong University | CHINA |
South Australian Research and Development Institute (SARDI) | AUSTRALIA |
South East Vets | AUSTRALIA |
Technical University of Denmark | DENMARK |
Tecnológico de Monterrey | MEXICO |
The Queen Elizabeth Hospital | AUSTRALIA |
Universidade Sao Francisco | BRAZIL |
Universite Paris Cite | FRANCE |
University of Adelaide | AUSTRALIA |
University of Cagliari | ITALY |
University of Cambridge | UNITED KINGDOM |
University of Copenhagen | DENMARK |
University of Durham | UNITED KINGDOM |
University of Newcastle | AUSTRALIA |
University of Oxford | UNITED KINGDOM |
University of Queensland | AUSTRALIA |
University of San Francisco | UNITED STATES |
University of South Australia | AUSTRALIA |
University of Sydney | AUSTRALIA |
University of Technology Sydney | AUSTRALIA |
University of Virginia | UNITED STATES |
Vietnam National University of Agriculture | VIET NAM |
Walter and Eliza Hall Institute of Medical Research | AUSTRALIA |
Zaozhuang University | CHINA |
External engagement & recognition
Engagement/recognition | Year |
---|---|
Editorial Board Member ('Antimicrobials, Resistance and Chemotherapy')Frontiers in Microbiology |
2017 |
Guest Editor for a special issueEssays in Biochemistry |
2017 |
MemberAustralian Society for Antimicrobials |
2017 |
MemberAdelaide Protein Group, Australian Society for Biochemistry and Molecular Biology (ASBMB) |
2017 |
MemberAmerican Society for Microbiology |
2017 |
MemberThe Australian Society for Microbiology |
2017 |
MemberAustralian Society for Biochemistry and Molecular Biology (ASBMB) |
2017 |
Teaching & student supervision
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
109420 - Limiting the risk for bacterial antimicrobial resistance: providing insight into the potential role of polypharmacy in antimicrobial resistance development | Current |
Amyloids of microbial biofilms mediate the host-microbe relationship and pro/pre-biotics enterprise | Current |
Antimicrobial resistance profiles and mechanisms of resistance in bacteria isolated from healthcare settings. | Current |
Combatting antimicrobial resistance through the development of responsible antimicrobial formulations with a reduced risk of causing resistance to clinically useful antibiotics | Current |
How Gut-Bacteria can Induce Heterogeneity in Dementia Pathology and Influence Drug Targeting | Current |
Preventing chronic infection in Cystic Fibrosis patients with a repurposed drug that inhibits antibiotic efflux pumps | Current |
Risk factors in the development and dissemination of antimicrobial resistance in residential age care facilities | Current |
Understanding resistance in critically important pathogens as a basis for antimicrobial drug discovery | Current |
A combined in silico and microbiological approach for the identification of novel efflux pump inhibitors against AcrAB-TolC | Completed |
Characterisation of antimicrobial resistance in hospital wastewater populations with in-depth analysis of Klebsiella oxytoca | Completed |
Characterisation of antimicrobial resistance in Pseudomonas aeruginosa and Escherichia coli from clinical and environmental settings | Completed |
Inhibitors of efflux to reverse resistance in Escherichia coli | Completed |
Investigation of the activity of a caspofungin-grafted surface coating on attaching pathogenic fungi | Completed |
Reversing antimicrobial resistance with inhibitors of drug efflux pumps | Completed |
Reversing multi-drug resistance with efflux pump inhibitors | Completed |
Surveillance and genomic characterisation of antimicrobial-resistant klebsiella spp. from healthcare environments in Adelaide, Australia | Completed |
Targeting bacterial cellular division via FtsZ as an approach in the development of new antimicrobial agents | Completed |